Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

Core Insights - Azitra, Inc. is a clinical stage biopharmaceutical company focused on precision dermatology, reporting significant progress in its clinical programs for treating major dermatological diseases [1][3]. Q2 2025 and Recent Business Highlights - The first half of 2025 was crucial for Azitra, achieving key milestones in its live biotherapeutic candidates, particularly for ATR-12 targeting Netherton syndrome, with promising safety data reported [3]. - Azitra announced the design of a Phase 1/2 trial for ATR-04, aimed at treating EGFRi-associated rash, which affects approximately 150,000 patients annually in the U.S. [3][8]. - The company expects to begin dosing the first patient in the ATR-04 trial in Q3 2025, indicating a milestone-rich remainder of the year [3]. Pipeline and Anticipated Milestones - Azitra's lead program, ATR-12, is in a Phase 1b clinical trial for Netherton syndrome, a rare skin disease with no approved treatments [5]. - ATR-04 is also in a Phase 1/2 clinical trial for EGFRi-associated skin toxicity, with Fast Track designation from the FDA [5][6]. - Key upcoming milestones include the first patient dosing for ATR-04 in Q3 2025 and topline data for ATR-12 in Q1 2026 [7]. Financial Results for the Quarter Ended June 30, 2025 - Research and Development (R&D) expenses were $1.4 million, up from $1.1 million in the same period of 2024 [7]. - General and Administrative (G&A) expenses remained stable at $1.5 million compared to the previous year [7]. - The net loss for the quarter was $2.9 million, compared to $2.6 million in Q2 2024, with cash and cash equivalents at $1.0 million as of June 30, 2025 [7][12].